David Berz
155 works · 1,885 citations · h-index 20
Top works
- Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription
- A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma
- Cryopreservation of hematopoietic stem cells
- Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
- Left sided inferior vena cava duplication and venous thromboembolism: case report and review of literature
- Survival of Patients with Squamous Cell Malignancies of the Upper Urinary Tract
- Nonengraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism
- Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers
- HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study
- Cremophor-Induced Lupus Erythematosus-Like Reaction with Taxol Administration: A Case Report and Review of the Literature
- Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer
- Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
- Marrow cell genetic phenotype change induced by human lung cancer cells
- Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors
- Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)
- Pneumonectomy After Neoadjuvant Chemotherapy and Radiation for Advanced-Stage Lung Cancer
- Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
- Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer
- Disparities in Compliance With National Guidelines for the Treatment of Malignant Pleural Mesothelioma
- MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy